Latin America Therapeutic Vaccines Market Research Report – Segmented By Disease Type (Autoimmune Disease, Cancer, Neurological Disease, Infectious Disease) and Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Size, Share, Trends & Growth Forecast (2022 to 2027)
Latin America Therapeutic Vaccines Market Size (2022 to 2027)
The Latin American Therapeutic Vaccines Market size is estimated to grow USD 2185.66 Million by 2027, from the current value of USD 487.43 Million in 2022, growing at a CAGR of 35% between 2022 to 2027.
Several approaches are being developed to boost the immune response to various infectious and cancerous cells in the pipeline. There are presently close to 120 new vaccines in the pipeline of various multinational companies across the globe set to hit the market in the next few years. Added to this, the vaccine market is relatively concentrated on both supply and demand sides. It is highly regulated and primarily dependent on public purchasers and donor policies. It has very distinct features that increase the complexity of assessing and understanding pricing and procurement in their context.
Coming to Latin America, Sanofi Pasteur, the vaccines division of Sanofi, announced that Brazil had granted regulatory approval to Dengvaxia®, representing the third successful licensure of the dengue vaccine, which was also approved in Mexico and the Philippines earlier in 2015. This, because Brazil is the fifth most populated globally and first in Latin America, is plagued by 1.4 million dengue patients. The remaining countries in Latin America also have a natural threat as they lie in the tropical Amazon basin, making them a hotbed for various epidemics.
An increase in funding’s from the government for vaccine development, a rise in investments by the major market players, rising prevalence of the disease, technological advancements, initiatives by NGOs are some of the factors that are propelling the Latin American therapeutic vaccines market growth.
However, massive capital expenditures and stringent regulatory policies, and high costs associated with treatment are a few factors inhibiting the market's growth.
This research report on the Latin American therapeutic vaccines market has been segmented and sub-segmented into the following categories:
By Disease Type:
- Autoimmune Disease
- Cancer
- Neurological Disease
- Infectious Disease
By Country:
- Brazil
- Mexico
- Argentina
- Chile
- Rest of Latin America
Geographically, the Latin American therapeutic vaccines market accounted for a minor share in the global market in 2020. The enormous rise in the prevalence of numerous chronic diseases, such as cancer, HIV, and cardiovascular diseases, has significantly impacted the Latin American market for therapeutic vaccines. The worrisome rise in the need for effective treatment has switched the attention in Latin America to therapeutic vaccinations. Several pharmaceutical companies have begun developing innovative vaccinations for diseases such as breast cancer, lung cancer, and Alzheimer's disease. Although these breakthroughs are still in the pipeline and have yet to be commercialized, they promise a bright future for the therapeutic vaccination business in Latin America.
Mexico is Latin America's largest market, and Brazil's market has significant growth potential, while Argentina's market is focused on discovering and developing novel vaccines.
KEY MARKET PLAYERS:
Companies playing a notable role in the Latin American therapeutic vaccines market covered in this report are GlaxoSmithKline, plc, Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
- Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
- Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
- Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
- Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
- Market Segmentation
5.1 By Disease Type
5.1.1 Autoimmune Disease Vaccines
5.1.2 Cancer Vaccines
5.1.2.1 Multikine
5.1.2.2 PR1 Peptide
5.1.2.3 TroVax
5.1.2.4 CYT004-MelQbG10
5.1.3 Neurological Disease Vaccines
5.1.3.1 ACC- 001
5.1.3.2 CAD 106
5.1.3.3 Parkinson's Disease Vaccine
5.1.3.4 Alzheimer's Disease
5.1.4 Infectious Disease Vaccines
5.1.4.1 Hepatitis C
5.1.4.2 HIV/AIDS
5.1.4.3 Other Infectious Disease
- Geographical Analysis
6.1 Introduction
6.2 Brazil
6.3 Argentina
6.4 Mexico
- Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
- Market Leaders' Analysis
8.1 GlaxoSMithKline plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent Biosolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune LLC
8.9 Pfizer Inc.
8.10 Sanofi Pasteur
- Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
- Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
- List of Tables
- List of Figures
- Latin America Therapeutic Vaccines Market, By Region, From 2022 - 2027 (USD Million)
- Latin America Therapeutic Vaccines Market, By Disease Type, From 2022 - 2027 (USD Million)
- Latin America Autoimmune Disease Vaccines Market, By Region, From 2022 - 2027 (USD Million)
- Latin America Cancer Vaccines Market, By Region, From 2022 - 2027 (USD Million)
- Latin America Neurological Disease Vaccines Market, By Region, From 2022 - 2027 (USD Million)
- Latin America Infectious Disease Vaccines Market, By Region, From 2022 - 2027 (USD Million)
- Latin America Cancer Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Latin America Multikine Market, By Region, From 2022 - 2027 (USD Million)
- Latin America PR1 Peptide Market, By Region, From 2022 - 2027 (USD Million)
- Latin America TroVax Market, By Region, From 2022 - 2027 (USD Million)
- Latin America CYT004-MelQbG10 Market, By Region, From 2022 - 2027 (USD Million)
- Latin America Neurological Disease Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Latin America ACC- 001 Market, By Region, From 2022 - 2027 (USD Million)
- Latin America CAD 106 Market, By Region, From 2022 - 2027 (USD Million)
- Latin America Parkinson's Vaccine Market, By Region, From 2022 - 2027 (USD Million)
- Latin America Alzheimer's Vaccine Market, By Region, From 2022 - 2027 (USD Million)
- Latin America Infectious Disease Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Latin America Hepatitis C Vaccines Market, By Region, From 2022 - 2027 (USD Million)
- Latin America HIV/AIDS Vaccines Market, By Region, From 2022 - 2027 (USD Million)
- Latin America Other Infectious Disease Vaccines Market, By Region, From 2022 - 2027 (USD Million)
- Brazil Therapeutic Vaccines Market, By Disease Type, From 2022 - 2027 (USD Million)
- Argentina Therapeutic Vaccines Market, By Disease Type, From 2022 - 2027 (USD Million)
- Mexico Therapeutic Vaccines Market, By Disease Type, From 2022 - 2027 (USD Million)
- Brazil Cancer Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Argentina Cancer Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Mexico Cancer Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Brazil Neurological Disease Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Argentina Neurological Disease Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Mexico Neurological Disease Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Brazil Infectious Disease Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Argentina Infectious Disease Vaccines Market, By Type, From 2022 - 2027 (USD Million)
- Mexico Infectious Disease Vaccines Market, By Type, From 2022 - 2027 (USD Million)
Related Reports
ASK FOR CUSTOMIZATION
Talk to our analyst and get customised report done according to your research needs
INQUIRE FOR DISCOUNT
Check if you can avail any discount. Submit your details and our team will get back to you.
DOWNLOAD FREE SAMPLE
Request to avail a free sample report that reflects this market and its growth.
